Does Pulmonary Rehabilitation improve the health of post tuberculosis patients living in Uganda?

Pulmonary Rehabilitation for post tuberculosis patients living in Uganda: Global RECHARGE Uganda

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18256843

Enrollment

114

Registered

2019-09-12

Start date

2020-11-13

Completion date

Unknown

Last updated

2023-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-TB lung disease Respiratory Chronic obstructive pulmonary disease, unspecified

Interventions

This trial will consist of a mixed-methods approach and recruitment for each stage will be separate. The trial consists of two stages: 1. Focus groups will be conducted with adults wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged = 18 years. 2. Willing and able to give consent to participate in the Pulmonary Rehabilitation and the follow-up schedule (signed or witnessed consent if the patient is illiterate). 3. Documented past history of smear positive PTB with treatment completed at least 6 months prior to study enrolment. 4. Negative Gene Xpert. 5. Medical Research Council dyspnoea grade of 2 or higher. 6. Able and willing to attend the full 12 weeks of Pulmonary Rehabilitation assessments.

Exclusion criteria

Exclusion criteria: 1. Has co-morbidities that preclude exercise e.g known unstable cardiovascular disease, locomotor difficulties. No age or gender restrictions apply. 2. Unwilling to participate for any reason. 3. Has any condition (social or medical) which in the opinion of the investigator would make study participation unsafe.

Design outcomes

Secondary

Measure	Time frame
1. Breathlessness is measured using the Medical Research Council (MRC) dyspneoa scale at 6 weeks. 2. Symptom severity is measured using the COPD Assessment Test at 6 weeks. 3. Health-related quality of life is measured using the Clinical COPD Questionnaire at 6 weeks. 4. Economic impact is measured using the Work Productivity and Activity Impairment questionnaire at 6 weeks. 5. Quality of life is measured using the EQ5D-5L questionnaire at 6 weeks. 6. Anxiety and depression are measured using the Hospital Anxiety and Depression Scale at 6 weeks. 7. Physical activity is measured using accelerometry at 6 weeks. 8. Pain is measured using the chest pain questionnaire at 6 weeks. 9. Exercise capacity is measured using the Endurance Incremental Shuttle Walk Test at 6 weeks. 10. Physical function is measured using the 5x Sit to Stand test at 6 weeks.	—

Measure

Time frame

1. Breathlessness is measured using the Medical Research Council (MRC) dyspneoa scale at 6 weeks. 2. Symptom severity is measured using the COPD Assessment Test at 6 weeks. 3. Health-related quality of life is measured using the Clinical COPD Questionnaire at 6 weeks. 4. Economic impact is measured using the Work Productivity and Activity Impairment questionnaire at 6 weeks. 5. Quality of life is measured using the EQ5D-5L questionnaire at 6 weeks. 6. Anxiety and depression are measured using the Hospital Anxiety and Depression Scale at 6 weeks. 7. Physical activity is measured using accelerometry at 6 weeks. 8. Pain is measured using the chest pain questionnaire at 6 weeks. 9. Exercise capacity is measured using the Endurance Incremental Shuttle Walk Test at 6 weeks. 10. Physical function is measured using the 5x Sit to Stand test at 6 weeks.

—

Primary

Measure	Time frame
Change in walking distance (exercise capacity) is measured using the Incremental Shuttle Walk Test (ISWT) at 6 weeks.	—

Countries

Uganda

Contacts

Public ContactMark Orme

mwo4@leicester.ac.uk01162583113

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 14, 2026